Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum
Contineum Therapeutics (NASDAQ: CTNM), a clinical-stage biopharmaceutical company focused on developing therapies for neuroscience, inflammation and immunology (NI&I) conditions, has announced its upcoming participation at the Stifel 2025 Virtual CNS Forum.
The company's management will deliver a presentation on Tuesday, March 18th at 12:30 p.m. ET. Interested parties can access the audio webcast through the Investors section of Contineum's website, where a replay will also be made available.
Contineum Therapeutics (NASDAQ: CTNM), una società biofarmaceutica in fase clinica focalizzata sullo sviluppo di terapie per condizioni di neuroscienze, infiammazione e immunologia (NI&I), ha annunciato la sua prossima partecipazione al Stifel 2025 Virtual CNS Forum.
La direzione dell'azienda presenterà un intervento martedì 18 marzo alle 12:30 p.m. ET. Le parti interessate possono accedere alla trasmissione audio tramite la sezione Investitori del sito web di Contineum, dove sarà disponibile anche una registrazione.
Contineum Therapeutics (NASDAQ: CTNM), una empresa biofarmacéutica en etapa clínica centrada en el desarrollo de terapias para condiciones de neurociencia, inflamación e inmunología (NI&I), ha anunciado su próxima participación en el Stifel 2025 Virtual CNS Forum.
La dirección de la empresa realizará una presentación el martes 18 de marzo a las 12:30 p.m. ET. Los interesados pueden acceder a la transmisión de audio a través de la sección de Inversores del sitio web de Contineum, donde también estará disponible una repetición.
Contineum Therapeutics (NASDAQ: CTNM)는 신경과학, 염증 및 면역학 (NI&I) 질환을 위한 치료법 개발에 중점을 둔 임상 단계의 생명공학 회사로, Stifel 2025 Virtual CNS Forum에 참여할 예정이라고 발표했습니다.
회사의 경영진은 3월 18일 화요일 오후 12시 30분 ET에 발표를 진행할 것입니다. 관심 있는 분들은 Contineum 웹사이트의 투자자 섹션을 통해 오디오 웹캐스트에 접속할 수 있으며, 재생도 제공될 예정입니다.
Contineum Therapeutics (NASDAQ: CTNM), une entreprise biopharmaceutique en phase clinique axée sur le développement de thérapies pour des conditions de neurosciences, inflammation et immunologie (NI&I), a annoncé sa prochaine participation au Stifel 2025 Virtual CNS Forum.
La direction de l'entreprise présentera une intervention le mardi 18 mars à 12h30 ET. Les parties intéressées peuvent accéder à la diffusion audio via la section Investisseurs du site web de Contineum, où une rediffusion sera également disponible.
Contineum Therapeutics (NASDAQ: CTNM), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Therapien für Neurowissenschaften, Entzündungen und Immunologie (NI&I) konzentriert, hat seine bevorstehende Teilnahme am Stifel 2025 Virtual CNS Forum angekündigt.
Die Unternehmensleitung wird am Dienstag, den 18. März um 12:30 Uhr ET eine Präsentation halten. Interessierte können über den Bereich Investoren auf der Website von Contineum auf den Audio-Webcast zugreifen, wo auch eine Wiederholung zur Verfügung stehen wird.
- None.
- None.
About Contineum Therapeutics
Contineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for NI&I indications with significant unmet need. Contineum is advancing a pipeline of internally-developed programs with multiple drug candidates now in clinical trials. PIPE-791 is an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis, progressive multiple sclerosis and chronic pain, and PIPE-307 is a selective inhibitor of the M1 receptor in clinical development for relapsing-remitting multiple sclerosis and major depressive disorder. For more information, please visit www.contineum-tx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250312676311/en/
Steve Kunszabo
Contineum Therapeutics
Senior Director, Investor Relations & Corporate Communications
858-649-1158
skunszabo@contineum-tx.com
Source: Contineum Therapeutics, Inc.
FAQ
When is Contineum Therapeutics (CTNM) presenting at the Stifel 2025 Virtual CNS Forum?
How can investors access Contineum Therapeutics' (CTNM) presentation at the Stifel CNS Forum?
What therapeutic areas does Contineum Therapeutics (CTNM) focus on?
What is the current development stage of Contineum Therapeutics (CTNM)?
